Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Company Overview - Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [3] - The company is developing precision-based therapies to improve the lives of patients and their families, utilizing modern neuroscience drug development tools across multiple therapeutic modalities [3] Key Developments - Vigil Neuroscience will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET [1] - The company's lead clinical candidate, Iluzanebart, is a fully human monoclonal antibody agonist targeting TREM2 for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare neurodegenerative disease [3] - Vigil is also developing VG-3927, a novel small molecule TREM2 agonist aimed at treating common neurodegenerative diseases, with an initial focus on Alzheimer's disease [3] Investor Relations - Vigil Neuroscience encourages investors to regularly check the "Investors" section of its website for important information [4] - The company provides contact information for investor relations and media inquiries, indicating a commitment to transparency and communication with stakeholders [5]